¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumor control dose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® ulcerating tumor ÇÑ±Û ±Ë¾ç¼º Á¾¾ç
¼³¸í   
  Á¾¾çÀǠǥ¸é¿¡ ±Ë¾çÀÌ ¹ß»ýÇϴ °Í. ´ë°³, ¸Å¿ì »¡¸® ÀÚ¶ó´Â Á¾¾ç¿¡¼­ Ç÷·ù °ø±ÞÀÌ Á¾¾ç¼¼Æ÷ÀÇ ÀÚ¶ó´Â ¼Óµµ¸¦ °¨´çÇÏÁö ¸øÇØ Á¾¾çÁ߽ɺΠÁ¶Á÷ÀÌ ±«»ç¿¡ ºüÁ® ±Ë¾çÀ» Çü¼ºÇϴ °æ¿ì°¡ ¸¹´Ù. À°¾ÈÀ¸·Î º¸¸é »¡°²°í, ¿­À̳ª¸ç, ÁöÀúºÐÇØ º¸ÀδÙ.
¿µ¹® brain tumor ÇÑ±Û ³úÁ¾¾ç
¼³¸í   
  ³úÁ¾¾çÀ̶õ ³ú¿Í ³úÁ¶Á÷¿¡¼­ »ý±ä Á¾¾çÀ» ÁöĪÇϴ ¸»ÀÌ´Ù. ±×·¯³ª ´ë°³ ³ÐÀº Àǹ̷Π»ç¿ëÇÒ °æ¿ì¿¡´Â ¸Ó¸®»À¼ÓÀÇ °ø°£ÀΠµÎ°³°­¼Ó¿¡ »ý±â´Â ¸ðµç Á¾¾çÀ» À̸£´Â ¸»·Î »ç¿ëµÈ´Ù.
  
  ³úÁ¾¾çÀº ÇÑÁ¤µÈ °ø°£ÀΠµÎ°³°­¿¡¼­ ¹ß»ýÇϹǷΠÁ¾¾çÀÌ ±×´ÙÁö Å©Áö ¾Ê¾Æµµ Á¤»óÀûÀΠÁ¶Á÷À» ¾Ð¹ÚÇϰԠµÇ°í, µÎ°³°­³»ÀÇ ¾Ð·ÂÀ» ³ôÀδÙ. ÀÌ·± Æ¯Â¡¿¡ ÀÇÇØ¼­ ³úÁ¾¾çÀÇ Áõ»óÀº ´Ù¸¥ Á¾¾ç°ú ´Þ¸®, Á¾¾ç ±× ÀÚüÀÇ Áõ»óº¸´Ùµµ µÎ°³³»¾Ð»ó½Â°ú Á¤»óÁ¶Á÷ÀÇ ¾Ð¹Ú¿¡ ÀÇÇÑ Áõ»óÀÌ ¸¹´Ù. µÎ°³³»¾Ð(³ú¾Ð)ÀÇ »ó½Â¿¡ ÀÇÇÑ Áõ»óÀ¸·Î´Â µÎÅë, ±¸ÅäµîÀÌ ÀÖÀ¸¸ç, Áö¼ÓÀûÀΠ³ú¾Ð»ó½Â¿¡ ÀÇÇØ¼­ À¯µÎºÎÁ¾(papilledema)ÀÌ °üÂûµÇ±âµµ ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀΠ³úÁ¶Á÷ÀÇ ¾Ð¹Ú°ú Á¾¾çÀÌ »ý±ä ºÎÀ§ÀÇ ±â´ÉÀÇ °áÇÕ¿¡ ³úÀÇ ±× ºÎºÐ¿¡ ÇØ´çÇϴ ±â´ÉÀÇ »ó½ÇÀ» º¸°ÔµÈ´Ù.
¿µ¹® epithelial tumor ÇÑ±Û »óÇǼºÁ¾¾ç
¼³¸í   
  Á¤»ó »ç¶÷ÀÇ Á¶Á÷Àº Ã¼Ç¥¸éÀ» µ¤´Â ¿ªÇÒÀ» Çϴ Á¶Á÷°ú, ÁַΠ¹ß»ý±âÀÇ Á߹迱¿¡¼­ ºÐÈ­ÇÑ °£¿±Á¶Á÷¿¡¼­ À¯·¡Çϴ °áÇÕÁ¶Á÷, »À, ¿¬°ñ, Áö¹æ, ±ÙÀ°, Ç÷°ü µîÀÇ Á¶Á÷ÀÇ µÎ °èÅëÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù. ÀüÀÚ¸¦ »óÇǼº Á¶Á÷, ÈÄÀÚ¸¦ ºñ»óÇǼº Á¶Á÷À̶ó Çϸ砱נ°¢°¢À» ±¸¼ºÇϴ ¼¼Æ÷¸¦ »óÇǼº ¼¼Æ÷, ºñ»óÇǼ¼Æ÷¶ó ÃÑĪÇÑ´Ù. »óÇǼº ¼¼Æ÷¿¡¼­ ±â¿øÇϴ Á¾¾çÀÌ »óÇǼº Á¾¾çÀ̸ç, ±ÙóÀÇ Á¶Á÷À¸·Î Ä§Åõ³ª Ç÷·ù, ¸²ÇÁÀÇ Á¶Á÷À» Å¸°í ¿ø°Å¸®ÀÇ Àå±â·Î À̵¿ÇÏÁö ¾Ê´Â ¾ç¼ºÁ¾¾ç¿¡´Â ¼±Á¾, À¯µÎÁ¾ µîÀÌ ÀÖ°í ¾ç¼º°ú ¹Ý´ë·Î ±ÙóÀÇ Á¶Á÷À¸·Î Ä§Åõ, ¿ø°ÝÀå±â·Î ÀüÀÌÇϴ ¾Ç¼ºÁ¾¾çÀ» ¸ðµÎ ÅëĪÇÏ¿© ¾ÏÁ¾(carcinoma)À̶ó°í ÇÑ´Ù.
¿µ¹® medullary tumor ÇÑ±Û ¼öÁú¼º Á¾¾ç
¼³¸í   
  ¾ÏÀÇ º´¸®ÇÐÀûÀΠºÐ·ùÁß Çϳª. ¿©·¯ ±â°üÀÇ ¾Ï¿¡¼­ ³ªÅ¸³ª´Âµ¥ ÁַΠ°©»ó»ù¾ÏÀ̳ª À¯¹æ¾Ï¿¡¼­ º¸ÀδÙ.
¿µ¹® malignant tumor ÇÑ±Û ¾Ç¼ºÁ¾¾ç
¼³¸í   
  Á¤»óÀûÀΠÁ¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû-È­ÇÐÀû-»ý¹°ÇÐÀûÀΠ¹ß¾Ï ¹°ÁúÀÇ Àۿ렶Ǵ ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ­ Çü¼ºµÇ´Â Á¾¾ç. ¹«Á¦ÇÑÀÇ ¼¼Æ÷ºÐ¿­·Î ¸Å¿ì ¿Õ¼ºÇϰԠÁõ½ÄÇÏ¿© ÁÖÀ§Á¶Á÷À» ÆÄ±«-ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² È­Çй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ Ä«ÄʽþƸ¦ÀÏÀ¸ÄÑ Á×À½À» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀΠ°ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀΠ°ÍÀ» À°Á¾À̶ó ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glomus tumor
    Å丮Á¾¾ç, »ç±¸Á¾¾ç
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • granulosa-theca cell tumor
    °ú¸³³­Æ÷¸·¼¼Æ÷Á¾¾ç
  • homologous tumor
    µ¿Á¾Á¾¾ç
  • juxtaglomerular cell tumor
    Å丮°ç¼¼Æ÷Á¾¾ç, »ç±¸Ã¼¿·¼¼Æ÷Á¾¾ç
  • Krukenberg¡¯s tumor
    Å©·çÄ˹ö±×Á¾¾ç
  • Leydig cell tumor
    ¶óÀ̵ðÈ÷¼¼Æ÷Á¾¾ç
  • mixed germ cell tumor
    È¥ÇÕÁ¾ÀÚ¼¼Æ÷Á¾¾ç
  • mixed tumor
    È¥ÇÕÁ¾¾ç
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • melanotic neuroectodermal tumor
    ¸á¶ó´Ñ½Å°æ¿Ü¹è¿±Á¾¾ç, Èæ»ö½Å°æ¿Ü¹è¿±¼ºÁ¾¾ç
  • mesenchymal tumor
    Áß°£¿±Á¾¾ç
  • mesodermal tumor
    Á߹迱Á¾¾ç
  • metastatic tumor
    ÀüÀÌÁ¾¾ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • radiation dose
    ¹æ»ç¼±·®
  • radiation absorbed dose
    Èí¼ö¼±·®
  • skin dose
    ÇǺμ±·®
  • therapeutic dose
    Ä¡·á¿ë·®, Ä¡·á¼±·®
  • high-dose
    °í¿ë·®
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • tumor antigen
    Á¾¾çÇ׿ø
  • tumor suppressor gene
    Á¾¾ç¾ïÁ¦À¯ÀüÀÚ
  • tumor marker
    Á¾¾çÇ¥ÁöÀÚ
  • tumor size
    Á¾¾çÅ©±â
  • tumor
    Á¾¾ç
  • adenomatoid tumor
    »ù¸ð¾çÁ¾¾ç, »ùÁ¾´àÀºÁ¾¾ç
  • benign tumor
    ¾ç¼ºÁ¾¾ç
  • carcinoid tumor
    Ä«¸£½Ã³ëÀ̵åÁ¾¾ç
  • cystic tumor
    ³¶Á¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • tumor necrosis factor
    Á¾¾ç±«»çÀÎÀÚ
  • genitourinary tumor
    ºñ´¢»ý½ÄÁ¾¾ç
  • glomus tumor
    Å丮Á¾¾ç, »ç±¸Á¾¾ç
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • gross tumor volume
    ¸Ç´«Á¾¾çüÀû
  • tumor suppressor gene
    Á¾¾ç¾ïÁ¦À¯ÀüÀÚ
  • heterogenous tumor
    ÀÌÁúÁ¾¾ç
  • homologous tumor
    µ¿Á¾Á¾¾ç
  • hormone dependent tumor
    È£¸£¸óÀÇÁ¸Á¾¾ç
  • infiltrating tumor
    ħÀ±Á¾¾ç
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • melatonic neuroectodermal tumor
    ¸á¶ó´Ñ½Å°æ¿Ü¹è¿±Á¾¾ç
  • mesenchymal tumor
    Áß°£¿±Á¾¾ç
  • mesodermal tumor
    Á߹迱Á¾¾ç
  • metastatic tumor
    ÀüÀÌÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • infection control study
    °¨¿°°ü¸®¿¬±¸
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • injury control
    »óÇØ°ü¸®(Ë×Ì´Ë´Ëö).
  • predictive value of control signal
    Á¦¾î<´ëÁ¶>½ÅÈ£ÀÇ ¿¹ÃøÄ¡
  • pulse control unit
    ¸Æ¹Ú Á¶Àý ´ÜÀ§
  • quality control
    Á¤µµ°ü¸®
  • quality control
    ǰÁú°ü¸®(̰̤˴Ëö).
  • quality control
    È­Áú °ü¸®, ǰÁú°ü¸®
  • quality control program
    Á¤µµ°ü¸®°èȹ
  • quality control, QC
    ǰÁú°ü¸®, Á¤µµº¸Áõ, Á¤µµ°ü¸®
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®, Áß°£À¯È¿·®.
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®.
  • ED 50=ÊÝeffective dose 50%
    50% À¯È¿·®.
  • ED=ÊÝeffective dose
    À¯È¿·®.
  • ID50 (50% infectious dose)
    50% °¨¿°·®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • accuracy control
    Á¤È®¼º Á¶Àý
  • admission by legal control
    Á¶Ä¡ÀÔ¿ø.
  • air pollution control
    ´ë±â¿À¿°¹æÁö<±ÔÁ¦> (ÊÙËÑ̤<˻̡>).
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý.
  • biologics control
    »ý¹°Á¦Á¦°ËÁ¤(ÊÙÌ¡Ì¡Ë§Ëø).
  • biologics control
    »ý¹°Á¦Á¦°ËÁ¤(¡­ð²ð¥ËþïÒ).
  • biologics control laboratory
    [º´¸®,¹Ì»ý,±â»ý,¸é¿ª,¹ÙÀÌ,¿¹¹æ]»ý¹°Á¦Á¦°ü¸®½ÃÇè¼Ò(Ë×ËÑ̡̡˴ËöËàÌ´ËÛ).
  • biologics control laboratory
    º´¸®,¹Ì»ý,±â»ý,¸é¿ª,¹ÙÀÌ,¿¹¹æ»ý¹°Á¦Á¦°ü¸®½ÃÇè¼Ò(ßæÚªð²ð¥Î·ìµãËúÐá¶).
  • birth control
    °£ È£ »ê¾ÆÁ¦ÇÑ(ß§ä®ð¤ùÚ), ¼öÅÂÁ¶Àý(áô÷Ãðàï½).
  • birth control
    °£ È£ »ê¾ÆÁ¦ÇÑ(Ë×Ëâ̡̰). ¼öÅÂÁ¶Àý
  • bite control
    ±³ÇÕÁ¶Á¤(ÎáùêðàïÚ).
  • cancer control program
    ¾Ï°ü¸®°èȹ(ËâË´ËöË­Ì·), ¾Ï¿¹¹æ»ç¾÷.
  • case control study
    ȯÀÚ´ëÁ¶¿¬±¸.
  • cased control sutdy
  • combustion control
    ¿¬¼Ò°ü¸®(ÊÙË´Ëö).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • control
    "´ëÁ¶(ÓßðÎ), Á¶Àý(ðàï½), Á¦¾î(ð¤åÙ)"
  • control analysis
    ´ëÁ¶ ºÐ¼®(ÓßðÎÝÂà°)
  • control strengh
    Á¶Àý °­µµ(ðàï½Ë­Óø)
  • negative control
    À½Á¦¾î(ëäð¤åÙ)
  • negative gene control
    À½À¯ÀüÀÚÁ¦¾î(ëäë¶îîí­ð¤åÙ)
  • positive control
    "°¡Á¶Àý(ʦðàï½), ¾ç¼ºÁ¶Àý(åÕàõðàï½)"
  • positive gene control
    "°¡À¯ÀüÀÚÁ¶Àý(ʦë¶îîí­ðàï½), ¾ç¼ºÀ¯ÀüÀÚÁ¶Àý, (åÕàõë¶îîí­ðàï½)"
  • relaxed control
    ÀÌ¿Ï Á¶Àý(ì¬èÐðàï½)
  • respiratory control
    È£Èí Á¶Àý(ðàï½)
  • respiratory-control index
    È£Èí Á¶Àý Áö¼ö(ò¦â¦)
  • stereopopulation control
    ÀÔü±¸Á¶À̼ºÁúü(Ø¡ô÷ϰðãì¶àõòõô÷) Á¦¾î (ð¤åÙ)
  • stringent control
    ¾ö°Ý Á¦¾î (åñÌ«ð¤åÙ)
  • transcriptional control
    Àü»ç Á¦¾î(ï®ÞÐð¤åÙ)
  • translational control
    ¹ø¿ª Á¶Àý(Ûèæ»ðàï½)
  • zero time control
    ¿µ½Ã(çÍãÁ) ´ëÁ¶(ÓßðÎ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • LD = lethal dose
    Ä¡»ç·®
  • lethal dose [=LD]
    Ä¡»ç·®
  • maintenance dose
    À¯Áö¿ë·®
  • maximal acceptable dose
    ÃÖ´ëÇã¿ë¼±·®
  • maximum permissible dose [=MPD]
    ÃÖ´ëÇã¿ë(¼±)·®
  • median lethal dose
    50%Ä¡»ç·®, Æò±ÕÄ¡»ç·®
  • midbreast dose
    À¯¹æÁß¾ÓÁ¶»ç¼±·®
  • minimal effective dose
    ÃÖ¼ÒÀ¯È¿·®
  • permissible internal dose
    ³»ºÎÇã¿ë¼±·®
  • radiation absorbed dose
    ¶óµå, ¹æ»ç¼±Èí¼ö¼±·®
  • relative dose
    ºñ±³Á¶»ç·®, »ó´ëÁ¶»ç·®
  • single dose
    ÀÏȸ·®
  • skin dose
    ÇǺμ±·®
  • benign tumor
    ¾ç¼ºÁ¾¾ç
  • brown tumor
    °¥»öÁ¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MD Doctor of Medicine [Lat. Medicinae Doctor]; magnesium deficiency; main duct; maintenance dose; major...
MID maximum inhibiting dilution; mesioincisodistal; midinfarct dementia; minimum infective dose; minimum...
NSD Nairobi sheep disease; neonatal staphylococcal disease; neurosecretory dysfunction; night sleep depr...
STD selective T-cell defect; sexually transmitted disease; skin-to-tumor distance; skin test dose; sodiu...
TDF testis-determining factor; thoracic duct fistula; thoracic duct flow; time-dose fractionation; tissu...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CTDI Computed Tomography Dose Index
DDD Defined Daily Dose
DVH Dose Volume Histogram
DEF Dose Effect Factor
DI Dose Intensity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • plaque control
    ġŠÁ¶Àý
  • proper direction and control
    ÀûÀýÇÑ Áöµµ¿Í ÅëÁ¦
  • pulse control unit
    ¸Æ¹Ú Á¶Àý ´ÜÀ§
  • quality control program
    Á¤µµ °ü¸® °èȹ
  • reasonable emotional control
    ÇÕ¸®Àû Á¤¼­ Á¶Àý
  • regular control
    ±ÔÄ¢ÀûÀÎ Á¶Àý
  • self-control
    ÀÚ°¡ Á¶Àý¹ý
    °³ÀÎÀÇ ½Å³ä ¸ñÇ¥ ¹× ŵµ¿¡ µû¶ó¼­ ÀÚ±âÀÇ ÇൿÀ» ½º½º·Î Á¶ÀýÇÏ´Â °Í.
  • stringent control
    ¾ö°Ý Á¶Àý
  • sulfur dioxide control
    ÀÌ»êÈ­ Ȳ °¡½º ±ÔÁ¦
  • time gain control
    ½Ã°£ °ÔÀÎ Á¶Àý
  • venereal disease control
    ¼ºº´ °ü¸®
  • voice control
    À½¼º Á¶Àý
    ¸ñ¼Ò¸®¸¦ ÀÓÀÇ·Î Á¶ÀýÇÏ´Â °Í.
  • voluntary control
    ÀǽÄÀû Á¦¾î, ÀÇÀÇÀû Á¶Àý
  • water quality control
    ¼öÁú °ü¸®
  • absorbed dose conversion factor
    Èí¼ö¼±·® º¯È¯ °è¼ö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
minimal dose <pharmacology> The smallest amount of a drug or physical procedure that will produce a desired physiologic effect in an adult.
(05 Mar 2000)
minimal infecting dose <microbiology> The smallest quantity of infectious material regularly producing infection; usually expressed as I.D.50, the quantity causing infection in 50% of a suitable series of animals or cells (cell cultures).
(05 Mar 2000)
minimal lethal dose <pharmacology> The minimal dose of a toxic substance or infectious agent that is lethal, as assayed in various experimental animals (e.g., the least amount of diphtheria toxin that, on an average, kills a 250-g guinea pig within 96 hours after subcutaneous inoculation).
When followed by a subscript (generally "MLD50"), denotes the minimal dose that is lethal to a certain percentage (e.g., 50%) of animals so assayed, LD05.
See: lethal dose.
(05 Mar 2000)
minimal reacting dose The minimal dose of a toxic substance causing a reaction, as manifested in the skin of a series of susceptible test animals; the assay is based on the development of a characteristic, minimal but definite, "standard," focal inflammation (congestion and oedema, induration, degenerative changes, and desquamation of epidermal cells).
(05 Mar 2000)
cumulative dose The total dose resulting from repeated exposures to radiation of the same part of the body or of the whole body.
(05 Mar 2000)
curative dose The quantity of any substance required to effect the cure of a disease or that will correct the manifestations of a deficiency of a particular factor in the diet, effective dose used with therapeutically applied compounds.
Synonym: therapeutic dose.
(05 Mar 2000)
preventive dose The smallest amount of any substance that will prevent occurrence of symptoms of a disease or the consequences of a lack of a particular factor in the diet.
(05 Mar 2000)
high dose tolerance The induction of tolerance by exposure to high doses of antigen.
(05 Mar 2000)
sensitizing dose In experimental anaphylaxis, the antigenic inoculum that renders an animal susceptible (sensitive) to anaphylactic shock following a subsequent inoculum (shocking dose) of the same antigen (anaphylactogen).
(05 Mar 2000)
shocking dose In experimental anaphylaxis, the inoculum of antigen that causes anaphylactic shock in an animal sensitised by a previous inoculum (sensitizing dose) of the same antigen.
(05 Mar 2000)
skin dose The quantity of radiation delivered to the skin surface.
(05 Mar 2000)
daily dose The total amount of a remedy that is to be taken within 24 hours.
(05 Mar 2000)
depth dose The dose of radiation at a distance beneath the surface, including secondary radiation or scatter, in proportion to the dose at the surface.
(05 Mar 2000)
divided dose A definite fraction of a full dose; given repeatedly at short intervals so that the full dose is taken within a specified period, usually one day.
Synonym: fractional dose.
(05 Mar 2000)
dose 1. <pharmacology> A quantity to be administered at one time, such as a specified amount of medication.
2. <radiobiology> A general term denoting the quantity of radiation or energy absorbed. For special purposes it must be appropriately qualified. If unqualified, it refers to absorbed dose. Unit of absorbed dose is the rad. The SI unit is the gray (1 Gy = 1 J kg-1 = 100 R).
Origin: Gr. Dosis = a giving
(16 Dec 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • control
    Áö¹è;´Ü¼Ó;°ü¸®;°¨µ¶(±Ç);¾ïÁ¦;Á¦¾î;±ÔÁ¦;Á¦±¸(·Â);ÄÁÆ®·Ñ;ÅëÁ¦(°üÁ¦)¼ö´Ü;(±â°èÀÇ)Á¶Á¾(Á¦¾î)ÀåÄ¡;(½ÇÇèÀÇ)´ëÁ¶Ç¥ÁØ;´ëÁ¶±¸;¿µ¸Å¸¦ Áö¹èÇÏ´Â Áö¹è·É;(ÀÚµ¿Â÷°æÁֵ¼­ °£´ÜÇÑ ¼ö¸®¸¦ À§ÇÑ)°æÁÖ Áߴܱ¸¿ª;Á¦¾î;Áö¹èÇÏ´Ù;ÅëÁ¦(°üÁ¦)ÇÏ´Ù;°¨µ¶ÇÏ´Ù;°ü¸®ÇÏ´Ù;¾ïÁ¦(Á¦¾î)ÇÏ´Ù;(
  • control board
    Á¦¾î¹Ý
  • control booth
    (¶óµð¿À.TV)Á¦¾î½Ç;Á¶Á¤½Ç
  • control chart
    °ü¸®µµ(ƯÈ÷ Á¦Ç° ǰÁúÀÇ)
  • control clock
    ±âÁØ ½Ã°è(master clock)
  • control column
    Á¶Á¾·û(Â÷ÀÇ ÇÚµé½Ä Á¶Á¤°£)
  • control experiment
    ´ëÁ¶ ½ÇÇè
  • control grid
    (ÀüÀÚ°üÀÇ)Á¦¾î ±×¸®µå(°ÝÀÚ)
  • control group
    Á¦¾îÁý´Ü;Á¶Á¾ÀåÄ¡;´ëÁ¶±º(µ¿ÀϽÇÇè¿¡¼­ ½ÇÇè¿ä°ÇÀ» °¡ÇÏÁö ¾ÊÀº ±×·ì)
  • control lever
    =CONTROL STICK
  • control panel
    =CONTROL BOARD
  • control rod
    (¿øÀÚ·ÎÀÇ)Á¦¾îºÀ
  • control room
    °üÁ¦½Ç;(¿øÀڷ½ü³µîÀÇ)Á¦¾î½Ç;(¹æ¼Û±¹µîÀÇ)Á¶Á¤½Ç
  • control stick
    Á¶Á¾°£
  • control storage
    Á¦¾î±â¾ïÀåÄ¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á